March 27, 2020
Ono Pharmaceutical and Bristol-Myers Squibb said on March 26 that they have filed in Japan their dual I/O therapy pairing Opdivo (nivolumab) and Yervoy (ipilimumab) in combination with platinum-doublet chemotherapy for the treatment of unresectable advanced or recurrent non-small cell...read more